Endothelial bioreactor ameliorates endotoxemia sepsis in swine.
BACKGROUND
Severe sepsis involves a complex response including the activation of lots of cells, inflammatory mediators, and the hemostatic system. Central to this process is an alteration of endothelial cell function. Therefore, we investigated whether an endothelial bioreactor (EBR) would provide a new therapeutic approach to this clinical disorder.


METHODS
EBR was constructed using a cartridge which contained with nonwoven polytetrafluoroethylene seeded with porcine iliac artery endothelial cell (PIEC). Pigs were intravenously administered with 0.25 mg/kg lipopolysaccharide and immediately placed in an extracorporeal circuit with EBR or sham controls.


RESULTS
Compared with the sham group, EBR therapy resulted in significantly higher mean arterial blood pressure and significantly lower plasma von Willebrand factor, endothelin-1 and scores of lung injury. These alterations were associated with a significant survival advantage in the EBR group.


CONCLUSIONS
Timely intervention with EC therapy in a tissue-engineered bioreactor may improve cardiovascular performance and alter the natural history of endotoxemia sepsis.
Xie
Qionghong
Q
Division of Nephrology, Huashan Hospital, Fudan University, Shanghai, PR China.
Liu
Junfeng
J
Gu
Yong
Y
Ping
Yi
Y
You
Li
L
Zhong
Jianyong
J
Li
Yi
Y
Hasegawa
Hyo
H
Liang
Weimin
W
Lin
Shanyan
S
Ding
Feng
F
D000818:Animals; D019149:Bioreactors / Q000662:veterinary*; D001794:Blood Pressure; D042783:Endothelial Cells; D019332:Endothelin-1 / Q000097:blood; D019446:Endotoxemia / Q000473:pathology / Q000628:therapy*; D008168:Lung / Q000473:pathology; D018805:Sepsis / Q000473:pathology / Q000628:therapy*; D013552:Swine; D023822:Tissue Engineering; D014841:von Willebrand Factor / Q000378:metabolism
D019332:Endothelin-1; D014841:von Willebrand Factor